Reimbursement Support

Reimbursement Support Services Overview
Co-Pay Assistance Program
Genentech Access Solutions: Coverage and Reimbursement
Patient Assistance

The Genentech Access to Care Foundation was established to help qualified patients who:

  • Have unmet medical needs
  • Are uninsured or rendered uninsured by payer denial
  • Meet specific insurance, financial, and medical criteria

Qualified patients enrolled in the Genentech Access to Care Foundation may receive their Rituxan for RA free of charge.

 

Please contact the Genentech Access to Care Foundation at
(866) 681-3329 for more information.

Referrals for co-pay assistance

If privately or publicly insured patients have difficulty paying for their Rituxan for RA co-pay, co-insurance, or other expenses, Genentech Rheumatology Access Solutions can refer them to an independent, non-profit organization that supports RA.

Patients who are referred for co-pay assistance need not be enrolled in Genentech Rheumatology Access Solutions and can simply call 1-866-681-3261 for a referral. Co-pay assistance may be available for patients who are privately or publicly insured, including Medicare and Medicaid patients.

Genentech and Biogen Idec do not influence or control the operations of these independent, nonprofit organizations (INOs), but Genentech Rheumatology Access Solutions can assist patients to navigate the process of seeking co-pay assistance by making a referral that is appropriate based on a patient's diagnosis and by assisting with the application process.

We cannot guarantee co-pay assistance once a patient has been referred by Genentech Rheumatology Access Solutions. The INOs to which we refer patients each have their own criteria with regard to patient eligibility, including financial eligibility.

Referrals for Co-Pay Assistance

May we also suggest

INDICATION

Rituxan (rituximab) in combination with methotrexate is indicated for the treatment of adult patients with moderately- to severely- active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies.

Rituxan is not recommended for treatment of patients with severe active infections.

IMPORTANT SAFETY INFORMATION

BOXED WARNINGS

Rituxan administration can result in serious, including fatal, adverse reactions. These include:

WARNINGS AND PRECAUTIONS

Rituxan administration can also result in additional serious, including fatal, adverse reactions including:

Patients should be closely observed for signs of infection if biologic agents and /or DMARDs other than methotrexate are used concomitantly.

Common adverse reactions include infusion reactions and infections.

For additional safety information, please see the full prescribing information, including BOXED WARNINGS and Medication Guide.

Attention Healthcare Provider: Provide Medication Guide to patient prior to Rituxan infusion.

Indication & Safety INFORMATION

Please acknowledge that you have read the below Important Safety Information by checking the box at the bottom of the screen.

Check By checking this box, I verify that I have read this Important Safety Information and that I am a U.S. Health Care Professional.